Mandate

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.

Vinge's team consisted of Dain Hård Nevonen, Louise Nässén and Hilda Andreasson (Capital Markets and Public M&A) as well as Arvid Weimers, John Andrén and Olivia Carlsten (Banking and Finance).

Related

Vinge advises InArea on entering into a SEK 450 million credit agreement with SEB

InArea's new facilities agreement comprises a term loan and a revolving credit facility, replacing the company's existing facilities. The facilities agreement also includes an option to increase the lending framework through an incremental facility of up to SEK 200 million.
June 03, 2026

Vinge has advised the arrangers in connection with St1 Biokraft’s EUR 260 million financing

Vinge has advised the arrangers, ING Bank N.V., ABN AMRO Bank N.V., DNB Bank ASA, Nordea Bank Abp, OP Corporate Bank plc, Coöperatieve Rabobank U.A., SpareBank 1 Sør-Norge ASA and Swedbank AB, in connection with St1 Biokraft AB’s EUR 260 million financing.
June 03, 2026

Vinge advises Trinax Group in conjunction with the acquisition of AddMobile and Scudo Solutions

Trinax Group has acquired the Swedish company AddMobile and the Finnish company Scudo Solutions, which specialise in software for work order management and project and cost management respectively. The two acquisitions broaden the group’s offering across the entire value chain, from the client’s budget and costing to the contractor’s field work, whilst strengthening its geographical presence in Finland.
June 03, 2026